New study aims to predict who can skip surgery for rectal cancer

NCT ID NCT05524012

Ongoing Knowledge-focused Sponsor: Jena University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This pilot study is testing whether regular MRI scans and blood tests can accurately track how rectal cancer responds to pre-surgery treatment. The goal is to develop a way to predict complete remission without needing surgery. Forty adults with locally advanced rectal cancer will be followed to see if these non-invasive tools can guide personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a non-invasive way to predict which patients with rectal cancer can avoid surgery and still achieve a cure.
What could go wrong: This is a small pilot study with only 40 participants, so results may not apply to everyone. The approach is still experimental and needs larger trials to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADAPTIVE TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplastic Cells, Circulating rectal cancer rectal carcinoma rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADAPTIVE TREATMENT LOCALLY ADVANCED RECTAL CARCINOMA NEOADJUVANT TREATMENT RADIOTHERAPY

Contacts and locations

Locations

Department of Radiotherapy and Radiation Oncology, Jena University Hospital

Jena, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.